Description:The present invention relates to the field of healthcare technology, specifically to intelligent drug dosage optimization systems. It utilizes advanced mathematical modeling, particularly transcendental nonlinear equation solvers, to accurately determine personalized medication dosages. This system is designed to support rural and under-resourced healthcare environments where access to skilled medical professionals may be limited. The invention integrates patient-specific data such as age, weight, medical history, and real-time physiological parameters to recommend optimal drug dosages. It leverages artificial intelligence and numerical methods to solve complex pharmacokinetic and pharmacodynamic equations. The system ensures safer and more effective treatment outcomes by minimizing risks associated with underdosing or overdosing. Furthermore, the invention supports mobile and offline deployment to suit remote areas with poor internet connectivity. It bridges the gap in healthcare equity by providing intelligent decision support tools for rural healthcare workers.
Background of the invention:
In many parts of the world, particularly in rural and remote regions, healthcare delivery faces severe constraints: limited access to trained medical personnel, reduced infrastructure, inconsistent supply of diagnostic tools, and low bandwidth for electronic systems. Patients in these areas often suffer from delayed or approximate medical assessments, and treatment decisions—including drug dosages—are sometimes based on approximate rules of thumb, generalized clinical guidelines, or empirical observations rather than precise, patient‐specific computations. Such practices, although sometimes life‐saving under constrained circumstances, carry significant risk: overdosing can cause toxicity, organ damage, or death; underdosing may lead to subtherapeutic exposure, treatment failure, resistance (particularly in infectious diseases), or prolonged illness.
Drug dosage determination is a complex task. The pharmacokinetics (absorption, distribution, metabolism, excretion) of drugs vary enormously between individuals due to differences in age, weight, genetic factors, co‐morbidities (e.g. liver or kidney impairment), concurrent medications, hydration status, nutritional status, and disease states. Pharmacodynamics (how the drug acts on its target, dose response curves, side‐effects, therapeutic windows) also differ widely. In modern hospital settings, dosage is often guided by lab results (e.g., blood levels of drug or metabolites), imaging, and continuous monitoring. But in rural settings, many of these data are unavailable or delayed; laboratory facilities may be basic or absent; monitoring may be intermittent; internet connectivity may be unreliable or absent; even reliable power supply may be intermittent.
To compensate, many protocols use simplified dosing rules that depend only on weight or age, or use fixed dosing regimens standardized for population groups (e.g. per kilogram for pediatric patients). While these are better than pure guesswork, they inherently assume “average” patients; they fail to account for variations in metabolism, organ function, disease severity, or interactions with other medications. This can lead to significant under‐ or overestimation of effective dosage. Some clinicians attempt to adjust for known risk factors (e.g. reduce dose for elderly patients, or with known renal impairment), but without quantitative modeling, these adjustments are approximate and often conservative (leading maybe to underdosing) or may themselves incur risk.
Meanwhile, much academic work has been done on pharmacokinetic (PK) and pharmacodynamic (PD) modeling, sometimes using differential equations, compartmental models, data‐driven machine learning, or Bayesian approaches. Some tools are able to estimate parameters such as volume of distribution, clearance rates, half‐lives, bioavailability, etc. These can be used to model drug concentration over time, predict peak and trough levels, and thus allow dosage scheduling to maintain drug concentrations within a therapeutic window. However, many of these models lead to transcendental nonlinear equations when solving for certain parameters or when inverting functions (for example when one needs to solve for the time at which concentration reaches a certain level, or solve for dosage given a target concentration at given time points, or adjust for nonlinear elimination kinetics). Solving those transcendental nonlinear equations requires iterative numerical methods (e.g. Newton‐Raphson, fixed‐point iteration, spectral methods, or more advanced solvers), which are computationally nontrivial, need accuracy, need stability, and need calibration. In high‐resource settings, such tools often run on computers, perhaps server‐based, with full data inputs; but in rural settings, computation may need to be done on constrained devices (mobile phones, tablets), with partial data, intermittent connectivity, maybe using approximate input data.
In addition, medicine dosing guidelines often assume that input parameters (such as weight, renal function, body surface area, hepatic function) are available reliably. But in rural settings, often weight is estimated, renal function may only be approximated (if lab tests are available), and even historical medication records may be missing. Environmental conditions, nutritional status, comorbid infections (e.g. malaria, HIV, tuberculosis), high levels of dehydration, or parasitic load may alter drug kinetics unpredictably. A patient may have subclinical hepatic impairment, or malnutrition, which slows metabolism; or co‐infection or medications that speed metabolism or compete for clearance. These complicating factors make standard models less reliable for many rural patients.
Moreover, drug supply issues, dosing forms, and drug formulations may differ; generic versions may have variable bioavailability, storage conditions (heat, humidity) may degrade potency, and some medications may be manipulated locally (e.g. splitting tablets). All of these introduce variability into the “effective dose” actually delivered. Ensuring safety therefore requires modeling that can tolerate uncertain inputs, adjust for variability, and provide robust recommendations that minimize risk.
There is also the dimension of acceptability and usability. Rural healthcare workers are often overburdened, may have limited training in advanced mathematical modeling, and may not be comfortable with complex software. Systems that are too complex, or require too many inputs, are unlikely to be used. Also, connectivity issues (lack of 4G/5G/internet), unreliable power, or lack of calibration tools mean that solutions must be designed for robustness, offline capability, minimal user input, clear output, and perhaps suggestions or alternatives when data are missing or estimated. For example, in many locales, a rural clinic may have only a basic smartphone, minimal diagnostic equipment, perhaps occasional access to lab results, but frequent need to treat malaria, pneumonia, dehydration, HIV, or chronic non‐communicable diseases (e.g. hypertension, diabetes). The system must support a wide range of drugs (antibiotics, antivirals, antimalarials, antihypertensives, insulin, etc.) and be adaptable to drug classes with nonlinear kinetics (e.g. some antiretrovirals, some anti‐TB medications, some chemotherapeutic drugs) and drugs for which the therapeutic window is narrow.
There have been prior attempts to address these challenges. Some mobile apps exist that provide dose tables, calculators based on body weight, age, renal function, etc. Some EHR (electronic health record) systems in better‐resourced clinics offer decision‐support modules. Some research prototypes attempt to use machine‐learning to predict optimal dosage from patient‐features, or Bayesian adaptive dosing (updating predictions as data come in). Clinical guidelines sometimes include “dose‐adjustment” factors (e.g. reduce by 50% if creatinine clearance falls below X). But often these approaches do not solve the deeper mathematical problem of inversely computing dosage from target concentration curves under constrained or nonlinear pharmacokinetics, or do not include robust solvers for transcendental nonlinear equations, or do not adapt well to missing or imprecise data, or do not function offline or on low‐resource devices. Furthermore, many algorithms assume linear kinetics, or “average” parameter values, or do not model drug interactions, or do not explicitly account for variable bioavailability or patient‐specific parameters. Also, many systems require substantial infrastructure (connectivity, lab facilities) or require users with specialized training.
Given the prevalence of diseases in rural areas—both infectious and non‐communicable—and the increasing availability of mobile hardware even in remote regions, there is a pressing need to develop a method that bridges the gap: a smart, computational method that can perform dose optimization by solving nonlinear, transcendental equations arising from PK/PD models; that can take partial or approximate inputs; that can adjust for patient‐specific parameters (age, weight, organ function, nutritional status, comorbidity); that provides safe and effective recommendations; that works offline or with intermittent connectivity; that is user‐friendly for healthcare workers with limited mathematical/computational background; that is robust to uncertainties and variability (in drug formulation, in storage, in patient physiology).
The proposed invention responds to this need. It aims to deliver an intelligent drug dosage optimization system that leverages mathematical modeling including transcendental nonlinear equations, numerical solvers, adaptive modeling, and decision support. It will integrate with minimal required inputs, use estimation where data are missing, provide feedback on uncertainty, perhaps suggest safety margins, perform computations efficiently and reliably on low‐resource devices, and present outputs in clear, actionable form (e.g. dosage amount, interval, adjustments). It would significantly reduce the risk of dosing errors, improve therapeutic efficacy, shorten time to effective treatment, reduce adverse drug events, and improve outcomes in rural healthcare settings. Additionally, it may support training and capacity development—providing clinicians or health workers with rationales or suggested adjustments—thereby improving confidence.
In summary, the background shows that while pharmacokinetic and pharmacodynamic modeling is well established academically, there is a gap in translating these capabilities into rural‐appropriate, user‐friendly, robust systems that solve the mathematical challenges (including transcendental nonlinear equations) necessary for precise dosage optimization under uncertainty. The proposed invention seeks to fill that gap, improving patient safety and care quality in under‐serviced rural areas.
The core mathematical challenge at the heart of dosage optimization in pharmacokinetics lies in modeling the time-dependent behavior of drug concentrations in biological compartments (e.g., plasma, tissues) after administration. While simple cases such as single-compartment linear models with immediate release can be handled analytically, real-world pharmacokinetic profiles often involve multiple compartments, nonlinear absorption and elimination, and delayed-release mechanisms. These complexities typically lead to transcendental nonlinear equations, especially when backward calculations are required—such as determining the required dosage or interval from a desired concentration-time profile.
For instance, when drugs follow Michaelis-Menten kinetics for elimination (common in drugs that saturate metabolic pathways), solving for dosage involves equations that are not algebraically solvable. Even for relatively simple cases—like computing time-to-peak concentration under first-order kinetics—the inclusion of lag time, partial absorption, or variable clearance introduces transcendental forms such as:
Where C(t) is the concentration at time t, D is the dose, ka and ke are the absorption and elimination rate constants respectively, and Vd is the volume of distribution. Solving for DDD given a desired C(t) and known pharmacokinetic constants is not straightforward and requires iterative numeric techniques. These challenges are compounded when considering multi-dose regimens with accumulation, where steady-state concentrations and trough levels must be managed to stay within therapeutic windows.
Traditional clinical decision-making does not typically engage with this level of modeling, particularly in low-resource or rural contexts. Healthcare providers in these areas are unlikely to have access to computational tools capable of solving such equations, and certainly not in real-time or with minimal input. Existing clinical guidelines simplify dosage using broad population-based approximations, sacrificing precision for ease of use. These are often unsuitable for edge cases—such as underweight children, malnourished adults, patients with multiple co-morbidities, or those on interacting drug regimens.
Another key issue lies in inter-patient variability, which is often significantly higher in rural settings due to environmental, genetic, and nutritional factors. Bioavailability may be impaired in patients with gastrointestinal infections; metabolism may be altered due to chronic malnutrition or co-infection with diseases such as malaria or tuberculosis. For instance, tuberculosis patients in rural areas may be co-infected with HIV, have variable liver function due to prolonged exposure to hepatotoxic medications, and may have erratic access to medications. In such a context, standard “one-size-fits-all” regimens become dangerous.
Furthermore, polypharmacy is increasingly common even in rural populations, particularly among the elderly. The concurrent use of multiple medications introduces complex pharmacokinetic and pharmacodynamic interactions—some synergistic, some antagonistic, others simply modifying absorption, distribution, metabolism, or excretion (ADME). Modeling these interactions dynamically is extremely difficult without computational support. It is here that intelligent systems, embedded with advanced equation solvers, can transform care—allowing providers to assess combined drug effects in real time and modify dosage accordingly.
Unfortunately, most current software tools for pharmacokinetic modeling are not suitable for rural deployment. They are either desktop-based (e.g., NONMEM, Phoenix WinNonlin, MATLAB-based solvers), require specialized training, or depend on large databases and consistent internet connectivity. Even mobile apps that offer dose calculators typically rely on look-up tables or simple linear formulas, not on actual numeric modeling. These apps also do not offer transparency about underlying assumptions, nor do they adjust adaptively based on incomplete data or uncertainty.
By contrast, the proposed invention introduces a hybrid intelligent method that not only incorporates robust mathematical solvers for transcendental nonlinear equations, but also integrates heuristic adaptation when data are missing. For example, when renal function is unknown, the system could use estimated glomerular filtration rate (eGFR) from patient age and weight, while quantifying the uncertainty and adjusting the dose with a safety buffer. If a patient's weight is not measured but only visually estimated, the system might suggest a range of doses or prioritize safer lower thresholds while still achieving therapeutic efficacy.
The key innovation lies in the modular solver architecture, which allows the system to deploy simplified models when data is limited, and more complex multi-compartment or nonlinear models when additional data becomes available. The system prioritizes patient safety through conservative assumptions, real-time error bounds, and fallback strategies. For instance, if a calculated dose falls within a margin of error close to a toxic threshold, the system flags it and offers a safer alternative dose, while advising monitoring or clinical reassessment.
The numerical solvers integrated into the system are optimized for constrained environments. They are designed to run on low-power processors, such as those found in entry-level smartphones or tablets. This requires efficient implementation of iterative algorithms like the Newton-Raphson method, bisection method, and adaptive quadrature integration techniques—all tuned for memory and processor efficiency. Furthermore, caching strategies and modular computation allow partial results to be saved and reused, enabling faster response times and reduced computational load.
One particularly novel aspect of the invention is its contextual adaptation module. This module uses environmental and demographic data to adjust pharmacokinetic parameters dynamically. For example, in a region known to have high prevalence of malnutrition or liver impairment, the system adjusts baseline assumptions about clearance and bioavailability. This improves the accuracy of its recommendations even without individualized lab data, based on population-level trends. Such capabilities are especially useful in humanitarian settings, mobile health camps, disaster zones, and rural clinics with little to no laboratory infrastructure.
Additionally, the system’s user interface is designed for simplicity and clarity. Healthcare workers are guided through the input process with prompts, visual aids, and error checking. Warnings are issued if parameters appear inconsistent or dangerous (e.g., if the user inputs a weight of 12 kg for a 40-year-old adult). Recommendations are displayed in natural language along with optional detailed rationale. For instance, the system might say: “Based on estimated renal function and target therapeutic range, administer 250 mg every 8 hours. Maximum safe dose not to exceed 750 mg/day.” Clinicians can also access expanded explanations if desired.
Another advantage of this invention is its offline capability. All computation is performed locally. Drug libraries, parameter estimates, and solver modules are embedded within the application, with periodic updates provided when internet access becomes available. This allows the system to function even in completely disconnected environments, making it highly reliable in emergencies or in regions with unstable connectivity.
To ensure clinical reliability, the system can be validated against real-world pharmacokinetic data and regulatory guidelines. For each supported drug, the system includes published pharmacokinetic models and boundary conditions (e.g., toxic thresholds, minimum inhibitory concentrations). It also allows country-specific or institution-specific dosing protocols to be integrated, ensuring cultural and regulatory compatibility. This adaptability is critical for global deployment.
In future iterations, the system can incorporate machine learning modules that learn from past usage data (with user consent and proper anonymization). For example, if many clinicians in a given region override a suggested dose due to observed patient reactions, the system can adapt over time, suggest alternative initial doses, or flag potential mismatches between model predictions and real-world outcomes. This creates a learning health system that continuously improves in performance and safety.
From a broader perspective, the proposed system serves not just as a technical solution, but as a tool for health equity. It empowers rural health workers with a level of diagnostic and therapeutic precision that would otherwise be inaccessible. It improves patient outcomes, reduces medication errors, and contributes to rational drug use—critical for fighting antimicrobial resistance. It supports health systems in achieving universal health coverage by ensuring that even the most remote patients receive appropriate, individualized care.
Summary of the invention:
The proposed invention presents an intelligent drug dosage optimization method tailored specifically for rural patient care, utilizing advanced transcendental nonlinear equation solvers. It addresses the limitations of current dosing methods that rely on generalized guidelines and linear assumptions, which are often inadequate in low-resource settings with high patient variability and limited clinical data. The system leverages mathematical models from pharmacokinetics and pharmacodynamics, solving complex equations to compute precise, patient-specific dosages even in the presence of partial or uncertain input data. Designed to function efficiently on low-power devices such as smartphones or tablets, the solution is robust in offline environments and adaptable to a wide range of drug classes and clinical conditions. It empowers rural healthcare providers with actionable recommendations through a simple user interface, reducing the risk of underdosing, overdosing, and drug interactions. By bridging the gap between advanced clinical modeling and practical rural application, the invention enhances safety, treatment effectiveness, and healthcare equity, offering a scalable solution to improve medication management in underserved regions.
Brief description of the proposed invention:
The proposed invention functions as an integrated system for determining optimal drug doses for individual patients in rural or resource‐constrained settings, making use of mathematical modeling, numerical solvers, and adaptive inputs. It begins with gathering patient particulars such as age, gender, body weight, height, approximate body surface area if possible, nutritional status, hydration status, known comorbidities (such as kidney or liver disease, diabetes, cardiovascular disease), any concurrent medications, current or recent illness, any available lab values (for example serum creatinine, liver enzyme levels, possibly albumin or bilirubin), and any known allergies or drug sensitivities. Where lab values are unavailable or delayed, the system uses estimated values based on demographic data together with default population parameters adjusted for region or known epidemiological factors. The system also captures treatment goals (for example target therapeutic concentration, acceptable trough levels, peak levels, interval between doses) and safety thresholds, including known toxic levels, therapeutic windows, and maximum safe daily doses.
The invention stores internally a pharmacokinetic and pharmacodynamic database of supported drugs, including models that describe absorption rates, distribution volumes, metabolism (clearance rates), elimination kinetics, bioavailability, protein binding fractions, half‐life, and metabolic pathways. For certain drugs, models include nonlinear kinetics, such as capacity‐limited elimination (e.g. Michaelis‐Menten kinetics), or saturable absorption or elimination, first‐pass metabolism, delayed release or delayed absorption, multi‐compartment distribution (e.g. central and peripheral compartments, tissue binding), and models of drug interactions where metabolism is affected by other substances or by disease state. The system supports defining or selecting drug models appropriate for local generic formulations, including adjusting bioavailability where generic versions may differ from reference formulations.
After input collection, the system frames the desired dosage problem as a modeling problem: given patient specific parameters, given pharmacokinetic model for the drug, given target concentration‐versus‐time profile or acceptable concentration bounds (e.g. minimum effective concentration and maximum tolerated concentration), find a dosage schedule (dose size, route of administration, frequency, interval) that keeps concentration within those bounds, minimizes risk of toxicity, maximizes likelihood of efficacy, and accommodates constraints (e.g. maximum total daily dose, minimal interval between doses, adherence capacity, timing of doses relative to meals or other medications). This often involves solving for D (dose) given an equation that relates D, absorption, distribution, elimination, time between doses, accumulation, and patient clearance. In cases of simple first‐order elimination and linear pharmacokinetics, classical analytic or semi‐analytic formulas may suffice; but in many cases, because of saturable kinetics, lag times, variable absorption, nonlinear elimination, or drug–drug interactions, one must solve transcendental nonlinear equations. These equations may include exponential terms, delays, partitioning between compartments, and possibly integral terms if absorption or release is time‐spread or delayed. For example, equations might involve terms like e^(–k_e t), or integrals of rate constants over time, or Michaelis‐Menten denominators in the elimination part, or delay differential equations. Because these equations cannot in general be solved in closed form for ‘dose’ or ‘interval’ directly, iterative numerical methods are required.
The system implements numerical solver modules, including but not limited to methods such as Newton‐Raphson, secant method, bisection, fixed‐point iteration, or hybrid methods combining robustness and speed. Solvers are designed with safeguards against divergence, oscillation, or slow convergence. They incorporate error estimation and allow setting of convergence criteria (e.g. tolerance of solution, maximum number of iterations). The system’s architecture allows plug‐in of different solver strategies depending on model complexity, computational resources, and urgency. For example, if a rough estimate is sufficient, a simpler solver with looser tolerance may be used; if accuracy is paramount (e.g. narrow therapeutic window), a more precise solver and full model may be deployed.
Because in rural settings input data may be incomplete, imprecise, or delayed, the system includes estimation and approximation layers. When laboratory values are missing, demographic or epidemiological norms are used. If weight is estimated rather than measured, uncertainty is represented (e.g. “±x kg”) and the solver can compute a dosage range rather than a point dose. If organ function is unknown, conservative assumptions may guide the model. The system can warn users when input uncertainty is high and suggest safer regimens or more frequent monitoring. It can suggest alternative dosing when certain parameters are untrustworthy—for example if renal function is suspected low due to history but no lab values, it might reduce clearance rate accordingly for modeling.
The system is built for low resource deployment. All core drug models, solver code, parameter estimation modules, safety constraint databases are packaged into a mobile or tablet application that can run offline. Updates to drug models, pharmacokinetic parameters, or safety thresholds are pushed when connectivity is available; the system caches these updates. The app uses efficient computing practices: minimal memory footprint, optimized code, and where possible pre‐computing or tabulating portions of the model that are reusable across patients or drugs to reduce runtime load. For complex computations, if hardware permits, short‐cuts or approximations are offered that trade off precision for speed, with clear indication of potential error.
The user interface is designed to be intuitive for health workers with limited technical background. It prompts the user through input fields in simple language, including “age”, “weight”, “has kidney disease?”, “taking any other medicines?”, “last lab test for kidney (if known)”, “how many hours since last dose”, etc. It allows users to select from drop‐down lists or simple yes/no options for comorbidities. The system displays warning flags for unusual values or inconsistent entries. Once computation is done, the system provides a dosage recommendation that includes the amount, interval, route (if multiple routes are possible), duration, and if necessary, adjustment suggestions (e.g. reduce dose or extend interval in case of compromised organ function). It also shows expected concentration‐time curves optionally (if device display and training permit), showing peaks and troughs, and comparing those to therapeutic windows, so the clinician can visualize risk vs efficacy.
The system incorporates safety features. For drugs with narrow therapeutic indices, the system enforces constraints such as maximum daily dose, minimal safe interval, suggested monitoring of side effects. It flags when doses approach levels that may cause toxicity. It includes checks for drug–drug interactions from its database. If concurrent medications are known to share metabolic pathways or compete for elimination, these effects are modeled or approximated and doses adjusted accordingly. The system also logs recommendations and inputs for audit, for follow‐up, for clinician review, and for potential learning modules over time to refine models based on observed outcomes.
In deployment, the system can be used by rural clinics, community health workers, small health centers without full laboratory infrastructure, mobile health units, or telehealth providers assisting remote populations. Health workers can input what they know, even approximate data, and receive recommendations that are safer and more tailored than generic guidance. Over time, as more data are collected (even rough), local parameter estimates (population norms) can be refined, leading to better model calibration for the specific region or demographic group.
The system is adaptable to many drug classes: it is especially valuable for drugs where dosing impacts are sensitive (e.g. antibiotics with narrow margin, antimalarials, anti‐tuberculosis medicines, antiretrovirals, oncology agents, immunosuppressants, cardiovascular drugs with narrow windows). It also handles chronic medication dosing (e.g. for hypertension, diabetes, epilepsy) where steady‐state, accumulation, adherence, and interactions matter. It supports alternative dosing forms (oral, intravenous, intramuscular) where pharmacokinetics differ. It also handles special patient populations: children (neonates, infants, adolescents), elderly, pregnant women, patients with impaired organ function.
The proposed invention also contemplates mechanisms for training and guidance. It may embed educational modules or help screens explaining why certain inputs are needed, what pharmacokinetic terms mean, what happens when data are missing, what the therapeutic window is, so that users build understanding over time. It may include illustrative case examples, warnings about common errors (such as forgetting to adjust for renal function, or not accounting for time since last dose), and suggestions for monitoring (lab tests, adverse effects) when feasible.
To ensure safety and regulatory compliance, the system includes references to established guidelines (e.g. national formularies, WHO therapeutic guidelines, regionally acceptable dosing standards) and allows customization of drug libraries to local approval status and regional pharmacopoeias. It supports translation of units (e.g. mg, µg, international units), differing drug formulations, and adjusting for local differences in drug potency or bioavailability. The system supports logging and version control: which drug model version was used, which pharmacokinetic parameters, what input values, what assumptions about missing or estimated variables, to support transparency, review, auditing, and where possible regulatory oversight.
In real use, the invention improves patient safety by reducing risks of overdose (which can cause organ toxicity, side effects) and underdose (leading to suboptimal efficacy, resistance development especially with antimicrobials). It promotes efficient resource use (avoiding wasted medication, avoiding hospitalizations due to drug toxicity or treatment failure). It contributes to better adherence by providing regimens that are simpler or optimized for local schedule constraints. It supports more rational use of medicines, which contributes to controlling antimicrobial resistance, preserving drug effectiveness in the long term.
The system is designed to scale. It is possible to deploy to many rural clinics, monitor usage, aggregate anonymized data to examine trends in input uncertainties, deviations from predicted vs actual outcomes (where follow‐up data are available), and over time refine the underlying pharmacokinetic models or region‐specific parameter distributions. It can enable health authorities to assess population level variations, see where generic formulations may differ, where adverse event rates are elevated, or where dosing guidelines may need local adaptation.
In summary, the proposed invention is a computationally intelligent, adaptive, safe, and usable system for optimizing drug dosage in rural health settings, combining mathematical rigor (including solving transcendental nonlinear equations), pragmatic approximations, user friendliness, offline reliability, safety constraints, and regionally relevant drug models, with the ultimate aim of improving treatment outcomes, reducing drug‐related risks, and enhancing equity in healthcare provision across remote, underserved populations.
The proposed invention is designed as an integrated, modular system to optimize drug dosing for individual patients in rural or resource-limited settings, where clinical data may be incomplete and healthcare infrastructure limited. At its core, the system gathers essential patient information, including demographics (age, sex, height, weight), physiological status (nutritional and hydration conditions), comorbidities such as kidney or liver disease, current medications, recent illnesses, laboratory values when available, and known allergies or drug sensitivities. When lab values or precise measurements are unavailable, the system intelligently estimates parameters using demographic norms, epidemiological data, and statistical inference, representing uncertainty where necessary.
Central to the invention is a comprehensive pharmacokinetic and pharmacodynamic (PK/PD) model repository encompassing a wide variety of drugs. Each drug model describes key parameters such as absorption rates, volumes of distribution, metabolic and elimination rates, protein binding, half-life, and nonlinear kinetics including Michaelis-Menten elimination or saturable absorption. The models also account for multi-compartment distribution, drug-drug interactions, and differences between generic and reference drug formulations, ensuring applicability to local medications and populations.
The dosing problem is formulated mathematically as an optimization task: given patient-specific variables, pharmacokinetic parameters, and therapeutic goals (target concentration ranges, dosing intervals, safety limits), the system calculates the dose size, frequency, and route that maintain drug concentration within effective and safe bounds. Many dosing equations involve nonlinear, transcendental forms incorporating exponential decay, integral terms, and saturation kinetics, which cannot be solved analytically for dose or interval. To address this, the system employs advanced numerical solvers such as Newton-Raphson, secant, and bisection methods, equipped with safeguards for convergence and error control. Solver selection adapts dynamically based on model complexity and urgency, trading off speed and precision as appropriate.
Recognizing the uncertainty inherent in rural healthcare data, the system includes estimation layers that impute missing laboratory values and physiological parameters, assign confidence intervals to inputs, and suggest conservative dosing regimens when data quality is low. Users are alerted to high-uncertainty inputs and advised to monitor patients more closely or pursue additional testing when feasible. Sensitivity analyses identify key variables influencing dose calculations, enabling prioritization of data collection efforts.
The entire platform is built for deployment on mobile devices and tablets with offline functionality, allowing use in remote locations without reliable internet connectivity. Updates to drug models, safety guidelines, and solver software are cached and synchronized opportunistically. The software is optimized for minimal computational load through efficient algorithms and precomputed lookup tables where applicable.
The user interface is designed for accessibility, guiding healthcare workers through simple, language-localized prompts for entering patient data and clinical goals. Input fields are validated to prevent errors, and dropdown menus or yes/no options simplify selections for comorbidities and medications. Upon completion, the system provides clear dosage recommendations including amount, frequency, route, and duration. Where device capabilities permit, concentration-time curves are displayed graphically to illustrate expected peaks and troughs relative to therapeutic windows, helping clinicians visualize efficacy and toxicity risks.
Safety features include enforcement of maximum dose limits, minimum dosing intervals, and interaction warnings based on an internal database of drug-drug and drug-disease interactions. The system flags doses approaching toxic levels and suggests monitoring parameters to mitigate adverse effects. Comprehensive logging records all inputs, assumptions, model versions, and outputs to facilitate audit, regulatory compliance, and clinical review.
The system is intended for use by rural clinics, community health workers, mobile health units, and telehealth providers supporting underserved populations. It enables tailored dosing even with incomplete data, improving patient safety by reducing risks of underdosing or overdosing, enhancing medication adherence through optimized schedules, and conserving limited healthcare resources by avoiding treatment failures and toxicity-related hospitalizations. Over time, aggregated anonymized data can refine local pharmacokinetic models and improve dosing accuracy for specific regions.
Applications span drugs with narrow therapeutic windows such as antibiotics, antimalarials, antiretrovirals, oncology agents, and cardiovascular medicines, as well as chronic disease treatments like hypertension and epilepsy. The system supports multiple administration routes and special populations including neonates, elderly patients, pregnant women, and those with organ dysfunction.
To promote user competence, the invention integrates educational content explaining pharmacokinetic principles, therapeutic windows, and the impact of missing or uncertain data. It provides case examples, common error warnings, and guidance on patient monitoring.
Compliance with national and international dosing guidelines is built in, and drug libraries are customizable for regional formulary differences. Units conversion and potency adjustments account for local variations in drug strength. The system’s architecture supports scalable deployment, data privacy, and secure update mechanisms.
In conclusion, this invention delivers a robust, adaptable, and user-friendly solution for personalized drug dosing in resource-limited environments, leveraging advanced pharmacological modeling and computational techniques to improve treatment outcomes, reduce drug-related harm, and promote equitable healthcare access worldwide.
 
, Claims:1. An integrated system for individualized drug dosage optimization comprising a patient data input module for demographics, clinical parameters, and lab values, and a pharmacokinetic/pharmacodynamic database tailored for rural healthcare settings.
2. The further including estimation algorithms that infer missing or uncertain patient parameters using demographic norms and epidemiological data to generate safe dosage ranges.
3. A computational engine that formulates drug dosing as a transcendental nonlinear equation and employs adaptive numerical solvers, including Newton-Raphson and bisection methods, to calculate optimal dosage schedules.
4. The system, wherein the solvers dynamically select solution strategies based on model complexity and urgency, incorporating safeguards against divergence and oscillation.
5. A mobile application platform designed for offline operation, incorporating minimal memory footprint, efficient computation, and caching mechanisms for updates in drug models and safety thresholds.
6. A user interface that guides healthcare workers through simplified input fields, provides warnings on data inconsistencies, and displays dosage recommendations including dose, frequency, route, and duration.
7. Safety modules that enforce dosing constraints such as maximum daily doses, minimum intervals, and flag potential drug–drug and drug–disease interactions to minimize toxicity risk.
8. The system supports multiple drug administration routes and special populations, including neonates, elderly, pregnant women, and patients with impaired organ function, by applying tailored pharmacokinetic models.
9. An audit and logging subsystem that records all user inputs, dosing calculations, assumptions, and model versions to support clinical review, regulatory compliance, and data-driven model refinement.
10. A training and educational module embedded within the system that provides explanations of pharmacokinetic concepts, therapeutic windows, and guidance on managing uncertain or missing data to improve user competency.